Vapreotide (trifluoroacetate salt)

Formulation: A lyophilized powder

Formal Name: D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-tryptophanamide, cyclic (2→7)-disulfide, trifluoroacetate salt

Purity: ≥95%

Formula Markup: C57H70N12O9S2 • XCF3COOH

Formula Weight: 1131,4

Shelf life (days): 1460

Notes: Vapreotide is a peptide neurokinin-1 receptor (NK1) antagonist and analog of somatostatin (IC50 = 330 nM in a radioligand binding assay).{39493} It inhibits increases in vascular permeability stimulated by substance P (Item No. 24035) in a concentration-dependent manner in isolated guinea pig trachea and main bronchi. Vapreotide (8 nmol per animal) reduces substance P-induced biting and scratching in mice. It increases reaction time to heat stimuli in the hot plate and tail flick tests when administered at a dose of 512 μg/kg, indicating antinociceptive activity in mice.{39494} Vapreotide reduces plasma growth hormone (GH) increases induced by phenobarbital (Item Nos. 9001494 / 20987), morphine (Item No. ISO60147), and chlorpromazine (Item No. 16129), hypoglycemia-induced glucagon elevation, and glucose-induced insulin secretion in rats.{39495} It also decreases tumor weight and volume in a hamster model of pancreatic ductal adenocarcinoma and suppresses tumor growth and reduces GH secretion in SK-ES-1 and MNNG/HOS osteosarcoma mouse xenograft models.{39496,39497}

• Artikelnummer: CAY24558-1
• Hersteller: Cayman Chemical
• Hersteller Artikelnummer: 24558-1
• Green Labware: Nein
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK